Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ANPCYNASDAQ:BIAFWOTCMKTS:DSRLFOTCMKTS:EPGNY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANPCYANGLEC$1.10C$1.02C$0.74▼C$2.74N/AN/A1,170 shs16 shsBIAFWbioAffinity Technologies$0.13+0.4%$0.17$0.12▼$2.90N/AN/A8,564 shs1,300 shsDSRLFDiaSorin$104.69$107.98$100.01▼$109.60$5.73B0.01100 shsN/AEPGNYEpigenomics$2.39$2.39$2.01▼$2.39N/AN/A100 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANPCYANGLE0.00%+31.03%+10.98%-40.43%-59.26%BIAFWbioAffinity Technologies0.00%+0.78%-23.98%-71.43%-61.76%DSRLFDiaSorin0.00%0.00%-3.96%+4.42%-3.95%EPGNYEpigenomics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANPCYANGLEN/AN/AN/AN/AN/AN/AN/AN/ABIAFWbioAffinity TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ADSRLFDiaSorinN/AN/AN/AN/AN/AN/AN/AN/AEPGNYEpigenomicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANPCYANGLE 0.00N/AN/AN/ABIAFWbioAffinity Technologies 0.00N/AN/AN/ADSRLFDiaSorin 2.00HoldN/AN/AEPGNYEpigenomics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANPCYANGLEN/AN/AN/AN/AN/AN/ABIAFWbioAffinity Technologies$8.81MN/AN/AN/AN/AN/ADSRLFDiaSorin$1.24B4.61$9.27 per share11.29N/A∞EPGNYEpigenomicsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANPCYANGLEN/A-C$0.48N/A∞N/AN/AN/AN/AN/ABIAFWbioAffinity TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ADSRLFDiaSorin$173.01MN/A0.00∞N/AN/AN/AN/A7/28/2025 (Estimated)EPGNYEpigenomicsN/A-$3.05N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANPCYANGLEN/AN/AN/AN/AN/ABIAFWbioAffinity TechnologiesN/AN/AN/AN/AN/ADSRLFDiaSorinN/AN/AN/AN/AN/AEPGNYEpigenomicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANPCYANGLEN/AN/AN/ABIAFWbioAffinity TechnologiesN/AN/AN/ADSRLFDiaSorinN/A3.121.89EPGNYEpigenomicsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANPCYANGLEN/ABIAFWbioAffinity TechnologiesN/ADSRLFDiaSorinN/AEPGNYEpigenomicsN/AInsider OwnershipCompanyInsider OwnershipANPCYANGLEN/ABIAFWbioAffinity TechnologiesN/ADSRLFDiaSorinN/AEPGNYEpigenomicsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANPCYANGLE173N/AN/ANot OptionableBIAFWbioAffinity Technologies10N/AN/ANot OptionableDSRLFDiaSorin3,18654.71 millionN/ANot OptionableEPGNYEpigenomics32N/AN/ANot OptionableEPGNY, ANPCY, BIAFW, and DSRLF HeadlinesRecent News About These CompaniesInsights in Genetics, Genomics and Epigenomics of Aging: 2025January 31, 2025 | frontiersin.orgEpigenomics Market Analysis, Technological Advancements, Key Applications, and Growth Forecasts from 2024 to 2032October 18, 2024 | taiwannews.com.twEpigenomics AG: Executive Board member Jens Ravens…April 30, 2024 | pharmiweb.comEpagny, Fribourg, Switzerland 10-Day Weather Forecaststar_ratehomeMarch 16, 2024 | wunderground.comEQS-News: Epigenomics AG publishes financial results for fiscal year 2023March 14, 2024 | markets.businessinsider.comEpigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive BoardJanuary 31, 2024 | pharmiweb.comEQS-News: Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive BoardJanuary 31, 2024 | markets.businessinsider.comEpigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)January 26, 2024 | pharmiweb.comSeminar SeriesJanuary 13, 2024 | case.eduEpigenomics articles from across Nature PortfolioDecember 5, 2023 | nature.comSBC Job OpportunitiesJoin our team!November 13, 2023 | uwyo.eduEQS-Adhoc: Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023October 10, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023October 10, 2023 | markets.businessinsider.comAn epic advance in epigenomics: Automated CUT&RUN enables chromatin profiling for scaled research & drug discovery applicationsSeptember 28, 2023 | labroots.comCardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in EpigenomicsSeptember 20, 2023 | finance.yahoo.comColon Ischemia: Don't Miss ThisSeptember 19, 2023 | medscape.comNew Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General MeetingSeptember 14, 2023 | benzinga.comEQS-News: Epigenomics AG publishes financial results for the first six months 2023August 10, 2023 | markets.businessinsider.comEpigenomics AG: Capital reduction planned at a ratio of 5 : 1August 2, 2023 | pharmiweb.comEpigenomics to Sell Patents, Biobank to New Day DiagnosticsJuly 24, 2023 | 360dx.comMedia Sentiment Over TimeEPGNY, ANPCY, BIAFW, and DSRLF Company DescriptionsANGLE OTCMKTS:ANPCYC$1.10 0.00 (0.00%) As of 05/23/2025ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.bioAffinity Technologies NASDAQ:BIAFW$0.13 +0.00 (+0.39%) As of 05/23/2025 This is a fair market value price provided by Polygon.io. Learn more.bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.DiaSorin OTCMKTS:DSRLF$104.69 0.00 (0.00%) As of 05/23/2025DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.Epigenomics OTCMKTS:EPGNY$2.39 0.00 (0.00%) As of 04/6/2023Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
